2025-08-28T14:16:53-07:00 2024-12-31 Crosby & Kaneda CPAs LLP 548 Market St PMB 97503 San Francisco CA 94104 990 2024-01-01 680087234 Scleroderma Research Foundation SCLE 4158349444 220 Montgomery St Ste 484 San Francisco CA 94104 Luke Evnin PhD Chairman 2025-08-28 true true Felix Gorrindo P01658413 5108352727 2024 2025-03-06 01:10:19Z Joanne Gold 220 Montgomery St Ste 484 San Francisco CA 94104 12395066 false X www.srfcure.org X 1987 CA The SRF is laser-focused on finding a cure for scleroderma by raising critical funds for research investments, fostering collaboration among the worlds top scientists and institutions to drive innovation, and raising awareness about this rare disease. 10 10 9 255 0 3932952 4457144 3832233 6657855 904546 1211667 -251693 -153505 8418038 12173161 2482921 3392838 0 891428 1606446 0 690399 3113250 4623237 6487599 9622521 1930439 2550640 18654748 32999784 7122391 18916787 11532357 14082997 X The mission of the Scleroderma Research Foundation is to fund and facilitate the most promising, highest quality research aimed at new treatments and, ultimately, a cure for scleroderma. false false 4201857 CONQUEST is a global, perpetual, clinical trial platform developed by the SRF in coordination with partner biopharmaceutical companies to accelerate the clinical development of agents for scleroderma. CONQUEST is designed to rapidly advance promising treatments for scleroderma and to identify those agents that should progress from phase 2b to phase 3 clinical trials. CONQUEST will make an enduring contribution to the scleroderma community by creating an ecosystem designed to enable rapid and efficient development of novel drugs for scleroderma patients. 3866057 3392838 6657855 The mission of the Scleroderma Research Foundation (SRF) is to find, fund, and facilitate the most promising, highest-quality research to cure scleroderma. We recruit the best and the brightest researchers to understand the causes, discover treatments, and ultimately eradicate this disease . At the SRF, research is at the center of all we do. Our Research Program is governed by the Board of Directors and supported by a volunteer Scientific Advisory Board comprised of some of the world's most highly regarded scientists who are leaders in their field of expertise. The Board of Directors and Scientific Advisors meet annually with researchers and clinicians from laboratories across the nation to select and fund the most promising scleroderma studies aimed at developing improved therapies to help patients live longer, fuller lives - and, ultimately, to find a cure for scleroderma. 474945 SRF Education & Awareness Program: Many patients hear the word scleroderma for the first time when they are diagnosed. We strive to raise awareness and provide educational resources because lack of awareness about scleroderma often causes delays in treatment or misdiagnosis. As an innovator in scleroderma research, the SRF is uniquely qualified to provide those living with this disease, the medical community, and the general public with the most up-to-date, trusted and relevant news and information about complications, treatments, and related research through our website, webinars, annual patient forum, and monthly eNewsletter. And we deliver stories of impact that connect and inspire patients, as well as address issues related to diversity, equity, and inclusion that patients may encounter as they navigate diagnosis, treatment, and living with the disease. The SRF Research Program: Led by a Scientific Advisory Board comprised of some of the most highly regarded scientists in the nation, the SRFs research program actively seeks out and recruits experts from the fields of rheumatology, immunology, genetics, and fibrosis, as well as, experts in cutting-edge technologies to join the scleroderma research community. With an intense focus on identifying projects and investigators likely to move scleroderma research forward, the SRF funds a diverse portfolio of projects led by top-tier investigators. 8542859 true true false false false false false false false true true false false false true true true false false false false false false false true false false true false true false false false false false false false false true false false false false false false false false true 43 0 true 9 true false false false false false true true false 0 false false false false false false false X 10 10 true false false false false false false false false false false true true true true true true true true false CA X X X Cindy Young Neha Pamboo 4158349444 220 Montgomery St Ste 484 SF CA 94104 Gregory Gordon Chief Medical Officer 40.00 0.00 416000 0 935 Joanne Gold Executive Dir. 40.00 0.00 X 215900 0 13936 Gloria Blecha VP Communications 40.00 0.00 171600 0 16022 Kate Ceredona Dir. Philanthropy 40.00 0.00 152258 0 7819 Hannah Young Dir. Communication 40.00 0.00 130007 0 7120 Luke Evnin PhD Chairman 30.00 0.00 X X 0 0 0 Susan Feniger Secretary 10.00 0.00 X X 0 0 0 Deann Wright Treasurer 10.00 0.00 X X 0 0 0 Omar Baker MD Board Member 2.00 0.00 X 0 0 0 Sharon Dobie MD Board Member 2.00 0.00 X 0 0 0 Eric Kau MD Board Member 2.00 0.00 X 0 0 0 David Knoller Board Member 1.00 0.00 X 0 0 0 Violetta Merin Board Member 2.00 0.00 X 0 0 0 Regina Hall Board Member 2.00 0.00 X 0 0 0 Jeff Seaman Board Member 2.00 0.00 X 0 0 0 1085765 45832 5 false true false Kelly Oliver 838 61st St Oakland CA 94608 CONQUEST consultant 375000 Lauretta Sue Fredrick 1121 Pinehurst Dr Chapel Hill NC 27517 CONQUEST consultant 288000 Rondaxe Pharmaceuticals 6443 Ridings Rd Ste 125 Syracuse NY 13206 CONQUEST consultant 287325 Latham & Watkins LLP 555 West Fifth St Ste 300 Los Angeles CA 90013 CONQUEST consultant 246509 Pharma e Market 200 Barr Harbor Dr Ste 400 W Conshohocken PA 19428 CONQUEST consultant 246072 9 15312 1074625 3367207 791295 4457144 Clinical trial platform 900099 6657855 6657855 6657855 1211667 1211667 0 0 0 0 68400 1074625 221905 -153505 0 0 0 12173161 6657855 1211667 X 3392838 3392838 0 0 0 650922 582826 34048 34048 0 824231 557760 51920 214551 0 48843 27538 5476 15829 82450 58197 5924 18329 0 207915 206783 1132 217508 217508 0 0 53131 53131 2271639 2230697 40942 158157 108412 3688 46057 28740 18357 4613 5770 134469 109282 709 24478 0 68430 54770 3415 10245 0 0 1084468 1069261 2776 12431 0 0 12094 9675 605 1814 123263 116463 5450 1350 Special event expenses 213555 213555 Bank and card fees 39990 39990 State registrations 9878 9878 0 9622521 8542859 389263 690399 3921428 13929113 12296 4012726 1071849 1269620 0 0 0 0 0 56574 203741 60945 41410 31629 19535 13488695 13267844 0 0 0 72277 297205 18654748 32999784 2842768 7245249 500000 300849 156432 3978774 11015106 7122391 18916787 X 11531310 13823997 1047 259000 11532357 14082997 18654748 32999784 2550640 X false true X true false X 3743217 3549644 5376802 3932952 4457144 21059759 0 0 3743217 3549644 5376802 3932952 4457144 21059759 4928365 16131394 347227 98683 116754 309318 781524 1653506 0 16529 7255 23784 22737049 10675619 0.70950 0.67990 X RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED 2953901 190225 231283 2912843 3069771 276423 392293 2953901 3453956 384185 3069771 1.00000 false false false 60945 41410 19535 19535 Due to partners 10714896 Operating lease liability 300210 11015106 X 12120030 12120030 53131 53131 12173161 9569390 9569390 53131 53131 9622521 Part V, Line 4: Intended uses of the endowment fund. The Bob Saget Memorial Scleroderma Research Fund was established as a board designated fund to hold contributions made to the Organization in tribute to Bob Saget and will be used to fund research grants. The intention of the board is that the fund maintain a minimum balance of $500,000. Part X : FIN48 Footnote The Internal Revenue Service and the California Franchise Tax Board have determined that the Organization is exempt from federal and state income taxes under IRC 501(c)(3) and California RTC 23701(d). The Organization has evaluated its current tax positions as of December 31, 2024 and is not aware of any significant uncertain tax positions for which a reserve would be necessary. The Organizations tax returns are generally subject to examination by federal and state taxing authorities for three and four years, respectively, after they are filed. false Cool Comedy 1143025 1074625 68400 14235 157443 50227 1143025 1074625 68400 14235 157443 50227 221905 -153505 true Boston Childrens Hospital Co 410 Park Dr Ste 602 Boston MA 02215 042774441 501c3 85978 0 Research Columbia University PO Box 29789 Gen Post Office New York NY 10087 135598093 501c3 119497 0 Research Duke University PO Box 602651 Charlotte NC 28260 560532129 501c3 27857 0 Research Georgetown Univ Medical Ctr PO Box 571164 Washington DC 20057 522218584 501c3 31710 0 Research Hospital for Special Surgery 535 E 70th St New York NY 10021 131624135 501c3 179872 0 Research John Hopkins University 12529 Collections Center Dr Chicago IL 60693 520595110 501c3 247841 0 Research Massachusetts GeneralHospital 55 Fruit St YAW2C Boston MA 02114 042697983 501c3 24632 0 Research Mayo Clinic PO Box 860334 Minneapolis MN 55486 416011702 501c3 17572 0 Research Medical Univ of SouthCarolina 1 South Park Cir B1 Ste 506 Charleston SC 29407 576028985 501c3 15027 0 Research Northwestern University 633 N St Clair 18-041 Chicago IL 60611 362167817 501c3 48563 0 Research Regents of the Univ Minnesota NW 5957 PO Box 1450 Minneapolis MN 55485 208367098 501c3 18059 0 Research Regents of UCLA 1125 Murphy Hall Los Angeles CA 90095 956006143 Government 108907 0 Research Regents of Univ of CA-UCSF 505 Parnassus Ave Box 0111 San Francisco CA 94143 946036493 Government 91433 0 Research Regents of Univ of Michigan Box 223131 Pittsburgh PA 15251 386006309 501c3 539738 0 Research Stanford School of Medicine PO Box 44253 San Francisco CA 94144 941156365 501c3 632077 0 Research Trustees of Dartmouth College 11 Rope Ferry Rd Ste 6210 Hanover NH 03755 020222111 501c3 131283 0 Research Trustees of the Univ of PA PO Box 785541 Philadelphia PA 19178 231352685 501c3 29519 0 Research Univ of TX Health Science Ctr PO Box 301418 Dallas TX 75303 741761309 Government 201338 0 Research University of Pittsburgh 3100 Cathedral of Learning Pittsburgh PA 15260 250965591 501c3 250000 0 Research University of Utah PO Box 581374 Salt Lake City UT 84158 876000525 Government 245399 0 Research USC S Figueroa St Ste 102 Los Angeles CA 90089 951642394 501c3 75000 0 Research Vanderbilt University Med Ctr PO Box 121236 Dallas TX 75312 352528741 501c3 80822 0 Research Yale University PO Box 208011 TAC 5669 New Haven CT 06520 060646973 501c3 115000 0 Research 19 4 Grantmaker's Description of How Grants are Used As part of the extensive continuing grant application process, grantees are required to provide a summary accounting of the grant from the prior funding year along with any remaining balances. This information, along with the proposed budget for the next funding cycle is reviewed by our Scientific Advisory Board (SAB) during the annual scientific workshop. The Board of Directors meets to discuss the SAB recommendations and funding decisions are agreed upon. X X false false false false false false false false false Gloria Blecha VP Communications 171600 16022 187622 Gregory Gordon Chief Medical Officer 416000 935 416935 Joanne Gold Executive Dir. 183500 32400 13936 229836 Kate Ceredona Dir. Philanthropy 152258 7819 160077 X 4 622295 FMV X Auction items 9 169000 FMV false false false Form 990, Part VI, Section A, Line 1a A separate Finance Committee reviews monthly financial performance and previews audit and tax returns prior to full Board review. Form 990, Part VI, Section A, Line 2 Luke Evnin (Chairman) is married to Deann Wright (Secretary). Form 990, Part VI, Section B, Line 11b A draft will be sent to the Finance Committee and once it clears their review, it will go to the full Board for approval. Form 990, Part VI, Section B, Line 12c Conflict of interest policy is discussed with all BOD members in annual review of Bylaws, members are asked to disclose any updates or changes that may conflict with the stated policy. Form 990, Part VI, Section B, Line 15a Market comparisons were done during initial recruitment, Recommendations for bonus/salary increases were based on industry standards and discussed/voted on during an executive session of the BOD meeting. Form 990, Part VI, Section B, Line 15b Process included review of publicly available compensation data, discussions with BOD to set salary max and bonus allowances as part of annual budgeting. If there is a request to exceed budgeted salary, BOD approval is required by vote. Form 990, Part VI, Section C, Line 19 Financial statements, bylaws, and conflict of interest policy are available upon request 990 Part IX, Statement of Functional Expenses In addition to the activity reflected in the financial statements, the Organization launched a platform clinical trial in 2024. As part of the launch, the Organization became responsible for significant clinical trial costs. Under agreements with external partnering corporations, the Organization receives funds in advance to be paid for clinical trial costs. The Organization reports such funds as Due to Clinical Trial. $9,220,087 in funds received and disbursed were related to this platform clinical trial; they were accounted for on a pass-through basis during the year ended December 31, 2024.